報價延遲最少15分鐘:2025/01/12 03:32 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
24.2 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
7.22/-3.73
|
|
企業價值
757.26M
|
| 資產負債 |
|
每股賬面淨值
11.42
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.22
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/12 03:32 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody. |